Thelansis

  Hope Medicine Inc., a clinical-stage innovative biopharmaceutical company, announced positive results from an interim analysis of a global Phase 2 study, titled “A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women with Moderate to Severe Endometriosis Associated Pain Over a 12-Week Treatment Period.” HMI-115 is a monoclonal antibody that blocks the prolactin receptor and serves as a first-in-class treatment for endometriosis. Publish Date: 24-10-2024   Source: Hope Medicine Inc. Endometriosis, a condition characterized by the abnormal proliferation of endometrial tissue similar to that lining the uterus but occurring outside it, manifests as endometrial implants in ectopic sites. These lesions are commonly found on organs such as the ovaries, Fallopian tubes, uterine surface, bowel, and pelvic cavity membrane (peritoneum), with less frequent occurrences in the vaginal, cervical, and bladder regions

  Kind Pharmaceutical, a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to AND017 for the treatment of Sickle Cell Disease (SCD). AND017 is being developed to treat various anemia indications associated with non-dialysis dependent chronic kidney disease (NDD-CKD) and dialysis-dependent chronic kidney disease (DD-CKD). Publish Date: 25-10-2024   Source: Kind Pharmaceutical Sickle cell disease (SCD) results from homozygous and compound heterozygote inheritance of a mutation in the β-globin gene. This genetic anomaly leads to the formation of dense and rigid red blood cells (RBCs), particularly those containing HbS or HbS in combination with other abnormal β alleles. When exposed to a deoxygenated environment, these RBCs undergo polymerization, becoming rigid and

  HiberCell, Inc., a clinical-stage biotechnology company focused on developing therapeutics to combat advanced cancer and cancer resistance, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HC-7366 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia. The FDA’s Fast Track program aims to facilitate the development and expedite the review of novel therapies designed to treat serious conditions and address significant unmet medical needs. Publish Date: 23-10-2024   Source: HiberCell, Inc. Acute myeloid leukemia (AML) is characterized by the uncontrolled growth of undifferentiated myeloid stem cells, accumulating immature myeloblasts. The standard approach to induce remission in AML has been a chemotherapy regimen combining cytarabine and anthracycline (commonly called “7+3”) for thirty years. However, relapse and refractory disease persist despite its long-standing use, with a median overall survi